Regenacy Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions. The company's selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/25/20 | $30,000,000 | Series A |
3E Bioventures Cobro Ventures  TA YA Venture Holdings Viva Biotech Yonjin Capital | undisclosed |
| 08/25/22 | $9,300,000 | Series B |
3E Bioventures Cobro Ventures Yonjin Capital | undisclosed |
